Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FS120 · 1 trial · 2 indications
Safety and tolerability will be evaluated by collection of AEs, SAEs and DLTs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
Toxicity will be evaluated according to the NCI CTCAE Version 5.0.
| Arm | Type | Description |
|---|---|---|
| FS120 | EXPERIMENTAL | Open-label study where FS120 will be administered as monotherapy or in combination with pembrolizumab in dose escalation and expansion cohorts |
| Name | Type | Description |
|---|---|---|
| FS120 | DRUG | Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity. |
Inclusion Criteria: * Measurable disease * Eastern Cooperative Oncology Group Performance Status 0-1. * Highly effective contraception if risk of conception exists * A female subject is eligible if not pregnant, not breastfeeding, not a woman of childbearing potential (WOCBP) or is a WOCBP that use...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
FS120 is an investigational small molecule being developed for the treatment of advanced cancer, including metastatic cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with advanced malignancies.
FS120 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical trials to evaluate the safety and efficacy of FS120 in patients with advanced cancer.
FS120 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being studied in clinical trials. The ongoing trial is a Phase 1/1b study in patients with advanced malignancies.
FS120 is being studied in a Phase 1/1b clinical trial with the identifier NCT04648202. This trial is titled 'FS120 Phase 1/1b Study in Patients With Advanced Malignancies' and is currently active but not recruiting. The study enrolls 82 participants with advanced or metastatic cancer.
No, the FS120 clinical trial is not randomized and does not use a control group. It is an uncontrolled study, meaning all participants receive FS120 without comparison to a placebo or standard treatment. The trial is also not double-blinded.
The FS120 clinical trial is being conducted in the United States and Spain. The study enrolls adults aged 18 years and older of all sexes. It is an open-label trial that does not include healthy volunteers.